Recombinant Human IL-29/IFN-lambda 1 Protein

• Reactivity: Hu
• Applications: Bioactivity

Recombinant Human IL-29/IFN-lambda 1 Protein Summary

• Additional Information: (NS0-expressed)
• Details of Functionality: Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED₅₀ for this effect is 1-5 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human IL-29/IFN-lambda 1 protein
  Gly20-Thr200, with a C-terminal 10-His tag
• Accession #: Q8IU54
• N-terminal Sequence: Gly20
• Protein/Peptide Type: Recombinant Proteins
• Gene: IFNL1
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 21.4 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 26-35 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-29/IFN-lambda 1 Protein

• cytokine Zcyto21
• IFNL1
• IFN-lambda 1
• IFN-lambda-1
• IL29
• IL-29
• interferon lambda-1
• interferon, lambda 1
• interleukin 29 (interferon, lambda 1)
• interleukin-29
• ZCYTO21

Background

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity) (1-3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor  beta (IL-10 R beta ) and a novel IL-28 receptor  alpha (IL‑28 R alpha , also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory region of the target genes. Human IL-29 cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and a 181 aa mature protein, which is a monomer in solution. It shares 67% and 69% aa sequence identity with human IL-28A and IL-28B, respectively.

1. Vilcek, J. (2003) Nature Immunol. 4:8.
2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

Publications for IL-29/IFN-lambda 1 (1598-IL)(45)

Publications using 1598-IL

• Grin, PM;Baid, K;de Jesus, HCR;Kozarac, N;Bell, PA;Jiang, SZ;Kappelhoff, R;Butler, GS;Leborgne, NGF;Pan, C;Pablos, I;Machado, Y;Vederas, JC;Kim, H;Benarafa, C;Banerjee, A;Overall, CM; SARS-CoV-2 3CLpro (main protease) regulates caspase activation of gasdermin-D/E pores leading to secretion and extracellular activity of 3CLpro Cell reports 2024-12-12 [PMID: 39673710] (Bioassay, Human)
• Moon, S;Han, S;Jang, IH;Ryu, J;Rha, MS;Cho, HJ;Yoon, SS;Nam, KT;Kim, CH;Park, MS;Seong, JK;Lee, WJ;Yoon, JH;Chung, YW;Ryu, JH; Airway epithelial CD47 plays a critical role in inducing influenza virus-mediated bacterial super-infection Nature communications 2024-04-30 [PMID: 38693120] (Bioassay, Mouse)
• Sehgal, PB;Yuan, H;Centone, A;DiSenso-Browne, SV; Oral Antiviral Defense: Saliva- and Beverage-like Hypotonicity Dynamically Regulate Formation of Membraneless Biomolecular Condensates of Antiviral Human MxA in Oral Epithelial Cells Cells 2024-03-28 [PMID: 38607029] (Bioassay, Human)
• M Tsai, W Osman, J Adair, R ElMergawy, L Chafin, F Johns, D Farkas, A Elhance, J Londino, RK Mallampall The E3 ligase subunit FBXO45 binds the interferon-lambda receptor and promotes its degradation during influenza virus infection The Journal of Biological Chemistry, 2022-11-13;0(0):102698. 2022-11-13 [PMID: 36379255] (Bioassay, Human)
• A Fedoriw, L Shi, S O'Brien, KN Smitheman, Y Wang, J Hou, C Sherk, S Rajapurkar, J Laraio, LJ Williams, C Xu, G Han, Q Feng, MT Bedford, L Wang, O Barbash, RG Kruger, P Hwu, HP Mohammad, W Peng Inhibiting Type I arginine methyltransferase activity promotes the T cell mediated antitumor immune response Cancer Immunology Research, 2022-04-01;0(0):. 2022-04-01 [PMID: 35181787] (Bioassay, Human)
• M Das, ML Smith, T Furihata, S Sarker, R O'Shea, KJ Helbig Astrocyte Control of Zika Infection Is Independent of Interferon Type I and Type III Expression Biology, 2022-01-15;11(1):. 2022-01-15 [PMID: 35053142] (Bioassay, Human)
• CF Hatton, RA Botting, ME Dueñas, IJ Haq, B Verdon, BJ Thompson, JS Spegarova, F Gothe, E Stephenson, AI Gardner, S Murphy, J Scott, JP Garnett, S Carrie, J Powell, CMA Khan, L Huang, R Hussain, J Coxhead, T Davey, AJ Simpson, M Haniffa, S Hambleton, M Brodlie, C Ward, M Trost, G Reynolds, CJA Duncan Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2 Nature Communications, 2021-12-07;12(1):7092. 2021-12-07 [PMID: 34876592] (Bioassay, Human)
• EA Monson, KM Crosse, M Duan, W Chen, RD O'Shea, LM Wakim, JM Carr, DR Whelan, KJ Helbig Intracellular lipid droplet accumulation occurs early following viral infection and is required for an efficient interferon response Nature Communications, 2021-07-14;12(1):4303. 2021-07-14 [PMID: 34262037] (Bioassay, Human)
• C Medaglia, AC Zwygart, PJ Silva, S Constant, S Huang, F Stellacci, C Tapparel Interferon Lambda Delays the Emergence of Influenza Virus Resistance to Oseltamivir Microorganisms, 2021-06-01;9(6):. 2021-06-01 [PMID: 34205874] (Bioassay, Human)
• HC Hawerkamp, A Domdey, L Radau, P Sewerin, P Oláh, B Homey, S Meller Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation Arthritis Research & Therapy, 2021-05-21;23(1):144. 2021-05-21 [PMID: 34020693] (Bioassay, Human)
• M Hayn, M Hirschenbe, L Koepke, R Nchioua, JH Straub, S Klute, V Hunszinger, F Zech, C Prelli Boz, W Aftab, MH Christense, C Conzelmann, JA Müller, S Srinivasac, CM Stürzel, I Forne, S Stenger, KK Conzelmann, J Münch, FI Schmidt, D Sauter, A Imhof, F Kirchhoff, KMJ Sparrer Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities Cell Reports, 2021-04-27;35(7):109126. 2021-04-27 [PMID: 33974846] (Bioassay, Human)
• X Zhao, C Li, X Liu, MC Chiu, D Wang, Y Wei, H Chu, JP Cai, I Hau-Yee Ch, K Kak-Yuen W, J Fuk-Woo Ch, K Kai-Wang T, KY Yuen, J Zhou Human Intestinal Organoids Recapitulate Enteric Infections of Enterovirus and Coronavirus Stem Cell Reports, 2021-02-12;16(3):493-504. 2021-02-12 [PMID: 33626333] (Bioassay, Primate - C. aethiops)
• M Syedbasha, F Bonfiglio, J Linnik, C Stuehler, D Wüthrich, A Egli Interferon-&amp;lambda Enhances the Differentiation of Naive B Cells into Plasmablasts via the mTORC1 Pathway Cell Rep, 2020-10-06;33(1):108211. 2020-10-06 [PMID: 33027651] (Bioassay, Human)
• CJ Stairiker, M van Meurs, LG Leon, AA Brouwers-H, L Rijsbergen, YM Mueller, PD Katsikis Heatr9 is an infection responsive gene that affects cytokine production in alveolar epithelial cells PLoS ONE, 2020-07-17;15(7):e0236195. 2020-07-17 [PMID: 32678841] (Bioassay, Human)
• M Essaidi-La, J Geiser, S Huang, S Constant, L Kaiser, C Tapparel Interferon-Dependent and Respiratory Virus-Specific Interference in Dual Infections of Airway Epithelia Sci Rep, 2020-06-24;10(1):10246. 2020-06-24 [PMID: 32581261] (Bioassay, Human)
• Y Chen, Y Wang, R Tang, J Yang, C Dou, Y Dong, D Sun, C Zhang, L Zhang, Y Tang, Q Dai, F Luo, J Xu, S Dong Dendritic cells-derived interferon-lambda1 ameliorated inflammatory bone destruction through inhibiting osteoclastogenesis Cell Death Dis, 2020-06-02;11(6):414. 2020-06-02 [PMID: 32488049] (Bioassay, In Vivo, Mouse)
• AM Kell, EA Hemann, JB Turnbull, M Gale RIG-I-like receptor activation drives type I IFN and antiviral signaling to limit�Hantaan orthohantavirus replication PLoS Pathog., 2020-04-24;16(4):e1008483. 2020-04-24 [PMID: 32330200] (Cell Culture, Human)
• JH Chung, SH Hong, N Seo, TS Kim, HJ An, P Lee, EC Shin, HM Kim Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency Cytokine, 2019-08-31;125(0):154833. 2019-08-31 [PMID: 31479875] (Bioassay, Human)
• C Good, AI Wells, CB Coyne Type III interferon signaling restricts enterovirus 71 infection of goblet cells Sci Adv, 2019-03-06;5(3):eaau4255. 2019-03-06 [PMID: 30854425] (Bioassay, Human)
• H Xu, SJ Xu, SJ Xie, Y Zhang, JH Yang, WQ Zhang, MN Zheng, H Zhou, LH Qu MicroRNA-122 supports robust innate immunity in hepatocytes by targeting the RTKs/STAT3 signaling pathway Elife, 2019-02-08;8(0):. 2019-02-08 [PMID: 30735121] (Bioassay, Human)
• I Angelidou, A Chrysantho, A Mitsios, S Arelaki, A Arampatzio, K Kambas, D Ritis, V Tsironidou, I Moschos, V Dalla, D Stakos, G Kouklakis, I Mitroulis, K Ritis, P Skendros REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1? Inflammatory Response in Active Ulcerative Colitis J. Immunol., 2018-04-30;0(0):. 2018-04-30 [PMID: 29712770] (Bioassay, Human)
• A Pierangeli, M Statzu, R Nenna, L Santinelli, L Petrarca, A Frassanito, M Gentile, G Antonelli, F Midulla, C Scagnolari Interferon lambda receptor 1 (IFNL1R) transcript is highly expressed in rhinovirus bronchiolitis and correlates with disease severity J. Clin. Virol., 2018-03-10;102(0):101-109. 2018-03-10 [PMID: 29549834] (Stimulation, Human)
• SS Kwek, S Watanabe, KR Chan, EZ Ong, HC Tan, WC Ng, MTX Nguyen, ES Gan, SL Zhang, KWK Chan, JH Tan, OM Sessions, M Manuel, J Pompon, C Chua, S Hazirah, K Tryggvason, SG Vasudevan, EE Ooi A systematic approach to the development of a safe live attenuated Zika vaccine Nat Commun, 2018-03-12;9(1):1031. 2018-03-12 [PMID: 29531213] (Cell Culture, Primate - Chlorocebus aethiops (African Green Monkey))
• AA Obajemu, N Rao, KA Dilley, JM Vargas, F Sheikh, RP Donnelly, RS Shabman, EG Meissner, L Prokunina-, OO Onabajo IFN-?4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling J. Immunol., 2017-10-25;0(0):. 2017-10-25 [PMID: 29070670] (Bioassay, Human)
• J Corry, N Arora, CA Good, Y Sadovsky, CB Coyne Organotypic models of type III interferon-mediated protection from Zika virus infections at the maternal-fetal interface Proc. Natl. Acad. Sci. U.S.A., 2017-08-07;0(0):. 2017-08-07 [PMID: 28784796] (Bioassay, Human)
• NA Ilyushina, VY Lugovtsev, AP Samsonova, FG Sheikh, NV Bovin, RP Donnelly Generation and characterization of interferon-lambda 1-resistant H1N1 influenza A viruses PLoS ONE, 2017-07-27;12(7):e0181999. 2017-07-27 [PMID: 28750037] (Bioassay, Human)
• PS Sung, SH Hong, JH Chung, S Kim, SH Park, HM Kim, SK Yoon, EC Shin IFN-?4 potently blocks IFN-? signalling by ISG15 and USP18 in hepatitis C virus infection Sci Rep, 2017-06-19;7(1):3821. 2017-06-19 [PMID: 28630501] (Bioassay, Human)
• V Oke, S Brauner, A Larsson, J Gustafsson, A Zickert, I Gunnarsson, E Svenungsso IFN-?1 with Th17 axis cytokines and IFN-? define different subsets in systemic lupus erythematosus (SLE) Arthritis Res. Ther., 2017-06-15;19(1):139. 2017-06-15 [PMID: 28619037] (ELISA (Standard), Human)
• Iva Gunnarsson Interferon (IFN)-? is a potential mediator in lupus nephritis Lupus Sci Med, 2016-11-22;3(1):e000170. 2016-11-22 [PMID: 27933198] (ELISA (Standard), Human)
• Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling Nat. Med., 2016-11-14;0(0):. 2016-11-14 [PMID: 27841874] (Bioassay, Human)
• Dengue virus infection induces interferon-lambda1 to facilitate cell migration Sci Rep, 2016-07-26;6(0):24530. 2016-07-26 [PMID: 27456172] (Bioassay, Human)
• Bordi L, Lalle E, Caglioti C, Travaglini D, Lapa D, Marsella P, Quartu S, Kis Z, Arien K, Huemer H, Meschi S, Ippolito G, Di Caro A, Capobianchi M, Castilletti C Antagonistic antiviral activity between IFN-lambda and IFN-alpha against lethal Crimean-Congo hemorrhagic fever virus in vitro. PLoS ONE, 2015-02-18;10(2):e0116816. 2015-02-18 [PMID: 25693189] (Bioassay, Human)
• Ding S, Khoury-Hanold W, Iwasaki A, Robek M Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol, 2014-01-07;12(1):e1001758. 2014-01-07 [PMID: 24409098] (Bioassay, Human)
• Cao Y, Zhang R, Zhang W, Zhu C, Yu Y, Song Y, Wang Q, Bai L, Liu Y, Wu K, Wu J IL-27, a cytokine, and IFN-lambda1, a type III IFN, are coordinated to regulate virus replication through type I IFN. J Immunol, 2013-12-11;192(2):691-703. 2013-12-11 [PMID: 24337382] (Bioassay, Human)
• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human)
• Popugaeva E, Witkowski PT, Schlegel M, Ulrich RG, Auste B, Rang A, Kruger DH, Klempa B Dobrava-Belgrade hantavirus from Germany shows receptor usage and innate immunity induction consistent with the pathogenicity of the virus in humans. PLoS ONE, 2012-04-24;7(4):e35587. 2012-04-24 [PMID: 22545121] (Control, Human)
• Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H, Tagawa M Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-lambda genes produced anti-tumour effects. Br. J. Cancer, 2011-09-27;105(9):1302-12. 2011-09-27 [PMID: 21952623] (Bioassay, Human)
• Zahn S, Rehkamper C, Kummerer BM, Ferring-Schmidt S, Bieber T, Tuting T, Wenzel J Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFN-lambda) in cutaneous lupus erythematosus. J. Invest. Dermatol., 2010-08-19;131(1):133-40. 2010-08-19 [PMID: 20720564] (Bioassay, Human)
• Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun., 2009-10-01;10(8):702-14. 2009-10-01 [PMID: 19798076] (Bioassay, Human)
• Bin L, Howell MD, Kim BE, Hall CF, Streib JE, Leung DY Inhibition of S100A11 gene expression impairs keratinocyte response against vaccinia virus through downregulation of the IL-10 receptor 2 chain. J. Allergy Clin. Immunol., 2009-07-03;124(2):270-7, 277.e1. 2009-07-03 [PMID: 19577285] (Bioassay, Human)
• Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer, 2009-07-15;125(2):367-73. 2009-07-15 [PMID: 19378341] (Bioassay, Human)
• Kato A, Peters A, Suh L, Carter R, Harris KE, Chandra R, Conley D, Grammer LC, Kern R, Schleimer RP Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps. J. Allergy Clin. Immunol., 2008-04-14;121(6):1385-92, 1392. 2008-04-14 [PMID: 18410958] (Bioassay, Human)
• Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, Thilo J, Asadullah K, Sterry W, Volk HD, Sabat R Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J. Leukoc. Biol., 2008-02-15;83(5):1181-93. 2008-02-15 [PMID: 18281438] (Bioassay, Human)
• Kato A, Favoreto S, Avila PC, Schleimer RP TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. J. Immunol., 2007-07-15;179(2):1080-7. 2007-07-15 [PMID: 17617600] (Bioassay, Human)
• Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine, 2005-07-21;31(2):109-18. 2005-07-21 [PMID: 15899585] (Bioassay, Human)

Bioinformatics

• Gene Symbol: IFNL1
• Uniprot:
  • Q8IU54()